论文部分内容阅读
快速室性心动过速(VT)/心室颤动(VF)是大多数心脏性猝死(SCD)的原因。有效终止VT/VF是预防SCD的基本策略。对于结构性心脏病和(或)伴有心功能障碍及急性心肌梗死的患者,有效的治疗措施有限。目前国内迅速起效的注射用Ⅲ类抗心律失常药物只有胺碘酮,但其有低血压、肝功能障碍、乳酸酸中毒等禁忌证。注射用盐酸尼非卡兰是一种新型Ⅲ类抗心律失常药物,日本、欧洲指南中已有临床应用的推荐。详细了解该药物特点,对临床增加治疗手段尤为重要。
Rapid ventricular tachycardia (VT) / ventricular fibrillation (VF) is the cause of most cardiac deaths (SCD). Effective termination of VT / VF is a basic strategy to prevent SCD. For patients with structural heart disease and / or cardiac dysfunction and acute myocardial infarction, effective treatment is limited. Currently the rapid onset of type III anti-arrhythmic drugs for injection only amiodarone, but it has low blood pressure, liver dysfunction, lactic acidosis and other contraindications. Nifedipine hydrochloride for injection is a new type III antiarrhythmic drug, which has been recommended for clinical use in Japanese and European guidelines. A detailed understanding of the characteristics of the drug, the clinical treatment is particularly important.